Sanjay Nayak - 26 May 2026 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Reporting relationship: Chief Strategy Officer
Issuer ticker: OCUL
Reported as of: 26 May 2026
Net transaction value: -$15,236
SEC form: 4
Accepted by SEC: 28 May 2026, 16:05:47 UTC
Prior SEC filing: 25 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Todd Anderman, Attorney-in-Fact for Sanjay Nayak

Key filing fact

Sanjay Nayak filed Form 4 for OCULAR THERAPEUTIX, INC (OCUL) on 28 May 2026.

Key facts

This page summarizes Sanjay Nayak's Form 4 filing for OCULAR THERAPEUTIX, INC (OCUL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 May 2026, 16:05.

Change

Previous filing in this sequence was filed on 25 Feb 2026.
Current net transaction value: -$15,236.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002012715 Primary reporting owner

Nayak Sanjay

Relationship: Chief Strategy Officer
Address: C/O OCULAR THERAPEUTIX, INC., 14 CROSBY DRIVE, 3RD FLOOR, BEDFORD
Signature: /s/ Todd Anderman, Attorney-in-Fact for Sanjay Nayak
Signature date: 28 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OCUL transaction

Common Stock

Sale

Transaction value: $15,236
Shares: -1,858
Change %: -0.56%
Price: $8.20
Shares after: 328,795
Date: 26 May 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2026. The sales do not represent a discretionary trade by the reporting person.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.1440 to $8.2512, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.